Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Sana Biotechnology, Inc. (SANA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
10/06/2023 4 Wilderotter Mary Agnes (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 2,077 shares @ $0
10/06/2023 4 Bishop Hans Edgar (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 6,925 shares @ $0
08/21/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with hypoimmune-modified primary human islet cells Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers Hosted R&D Day, showcasing broad portfolio across platforms, programs, and diseases Announced plan to develop SC291 in autoimmune disorders Shared preclinical data that transplanted allogeneic hypoimmune-modified islet cells evade rejection and control glucose without immunosuppression or insulin treatment in non-human primate diabetes study Data published in Science Translational Medicine, Natur..."
07/06/2023 4 Wilderotter Mary Agnes (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 1,245 shares @ $0
07/06/2023 4 Bishop Hans Edgar (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 4,152 shares @ $0
06/12/2023 4 NELSEN ROBERT (10% Owner) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 65,000 options to buy @ $6.7, valued at $435.5k
06/09/2023 4 REICIN ALISE (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 65,000 options to buy @ $6.7, valued at $435.5k
06/09/2023 4 Bilenker Joshua H. (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 65,000 options to buy @ $6.7, valued at $435.5k
06/09/2023 4 Seitz Michelle (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 65,000 options to buy @ $6.7, valued at $435.5k
06/09/2023 4 Wilderotter Mary Agnes (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 65,000 options to buy @ $6.7, valued at $435.5k
06/09/2023 4 Cole Douglas G. (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 65,000 options to buy @ $6.7, valued at $435.5k
06/09/2023 4 Yang Patrick Y (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 65,000 options to buy @ $6.7, valued at $435.5k
06/09/2023 4 Bishop Hans Edgar (Director) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Granted 65,000 options to buy @ $6.7, valued at $435.5k
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/08/2023 4 Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Sold 181,461 shares @ $6.3061, valued at $1.1M
Sold 22,297 shares @ $6.3061, valued at $140.6k
Sold 177,240 shares @ $6.2397, valued at $1.1M
Sold 22,760 shares @ $6.2397, valued at $142k
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 8-K Investor presentation
Docs: "CAR 4 CD22 CD19 BCMA GPRC5D"
05/26/2023 4 Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Sana Biotechnology, Inc.
Txns: Sold 308,290 shares @ $6.5652, valued at $2M
Sold 39,580 shares @ $6.5652, valued at $259.9k
Sold 102,245 shares @ $6.3522, valued at $649.5k
Sold 13,127 shares @ $6.3522, valued at $83.4k
Sold 72,670 shares @ $6.2265, valued at $452.5k
Sold 9,330 shares @ $6.2265, valued at $58.1k
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/24/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year"
05/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/01/2023 POS EX Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/26/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy